In March 2025, the company announced new options for any direct-to-client featuring of its Wegovy weight loss drug. The company proven a different pharmacy, referred to as NovoCare, which might charge prospects $499 each month for entry to the drug, fewer than 50 percent the price of the drug by way of other pharmaceutical distribution networks.[53